ANIX

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.

Wall Street analysts forecast ANIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIX is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Anixa Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Anixa Biosciences Inc. EPS for the last quarter amounts to -0.07 USD, decreased -30.00 % YoY.

Anixa Biosciences Inc (ANIX) has 5 emplpoyees as of December 17 2025.

Today ANIX has the market capitalization of 117.51M USD.